Claude Négrier

Title: **The Innovative Contributions of Claude Négrier**

Introduction

Claude Négrier, an accomplished inventor based in Irigny, France, has made significant strides in the field of genetic engineering and biotechnology. With a total of four patents to his name, Négrier’s work primarily focuses on the modification of Factor VIII cDNA, which holds promise for advancements in gene therapy.

Latest Patents

Négrier's latest patents include groundbreaking innovations involving a modified Factor VIII cDNA. One such patent describes a modified Factor VIII cDNA in which the B-domain of the wild-type Factor VIII cDNA is deleted and a truncated Factor IX intron 1 is inserted in various locations of the Factor VIII cDNA. This modification aims to enhance the yield of Factor VIII production both in vitro and as part of a transfer vector for gene therapy. Another significant patent outlines a similar modification wherein the B-domain is deleted, and two locations of the Factor VIII cDNA receive the truncated Factor IX intron 1. This version incorporates a cDNA promoter suitable for expression in hematopoietic cell lines, specifically targeting platelets.

Career Highlights

Throughout his career, Claude Négrier has been associated with Aventis Behring GmbH, where he has played a pivotal role in advancing therapeutic solutions through his innovative research. His dedication to improving genetic therapies showcases his expertise and commitment to the field.

Collaborations

Négrier has collaborated with esteemed colleagues, including Jean Luc Plantier and Jean-Luc Plantier. Together, they have contributed to the research community through teamwork in pioneering approaches to genetic modification and therapy.

Conclusion

As an inventor with a vision to improve medical treatments through genetic research, Claude Négrier stands out in his field. His patent innovations, particularly concerning Factor VIII cDNA modifications, present promising avenues for future research in gene therapy.